Dual Bronchodilator Therapy: A Review | Chapter 03 | Current Trends in Medicine and Medical Research Vol. 5
Inhaled bronchodilators with or without
inhaled steroids (IGCs) are the mainstay of pharmacological treatment for
stable obstructive airway diseases, including beta2-agonists and muscarinic
antagonists. Long-acting muscarinic antagonist bronchodilators (LAMA) and
long-acting β2-agonists (LABA) are the treatment of choice for moderate to
severe chronic obstructive pulmonary disease (COPD). Also some studies have
demonstrated the benefit of LAMA in the treatment of difficult-to-control
asthma and the potential use in asthma-COPD overlap (ACO). Control of airway
tone in health and disease states, cholinergic and adrenergic receptors,
signaling, molecular biology of mediators, and airway muscle contraction /
relaxation mechanisms are reviewed concisely and as they may be handled
pharmacologically. Subsequently, the evidence of the role of the LABA / LAMA
combination in the aforementioned entities, their complementary mechanisms of
action and other alternative mechanisms of action as well as potential
deleterious effects is discussed.
Author(s) Details
Alcibey Alvarado
Internal Medicine and
Neumology, Clínica de Diagnóstico Médico, San José, Costa Rica.
View Volume: http://bp.bookpi.org/index.php/bpi/catalog/book/135
Comments
Post a Comment